Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALEC NASDAQ:FLNA NASDAQ:HELP NASDAQ:NERV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALECAlector$2.12+0.5%$2.30$1.09▼$3.40$234.26M0.64574,647 shs898,480 shsFLNACassava Sciences$1.25+4.2%$1.72$1.16▼$4.98$57.97M-0.75405,167 shs401,271 shsHELPCybin$4.34+3.8%$5.07$4.15▼$9.83$215.82M0.81.11 million shs537,224 shsNERVMinerva Neurosciences$5.03+15.4%$6.27$1.35▼$12.46$203.13M-0.08129,901 shs414,909 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALECAlector+0.47%-1.40%-21.48%+5.47%+54.74%FLNACassava Sciences+4.17%+1.63%-27.75%-42.40%-44.20%HELPCybin+3.83%-16.22%-22.64%-37.10%+433,999,900.00%NERVMinerva Neurosciences+15.37%-9.37%-27.00%-20.66%+264.49%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALECAlector$2.12+0.5%$2.30$1.09▼$3.40$234.26M0.64574,647 shs898,480 shsFLNACassava Sciences$1.25+4.2%$1.72$1.16▼$4.98$57.97M-0.75405,167 shs401,271 shsHELPCybin$4.34+3.8%$5.07$4.15▼$9.83$215.82M0.81.11 million shs537,224 shsNERVMinerva Neurosciences$5.03+15.4%$6.27$1.35▼$12.46$203.13M-0.08129,901 shs414,909 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALECAlector+0.47%-1.40%-21.48%+5.47%+54.74%FLNACassava Sciences+4.17%+1.63%-27.75%-42.40%-44.20%HELPCybin+3.83%-16.22%-22.64%-37.10%+433,999,900.00%NERVMinerva Neurosciences+15.37%-9.37%-27.00%-20.66%+264.49%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALECAlector 2.13Hold$3.6370.99% UpsideFLNACassava Sciences 1.00SellN/AN/AHELPCybin 3.00Buy$58.751,253.69% UpsideNERVMinerva Neurosciences 2.00Hold$10.50108.75% UpsideCurrent Analyst Ratings BreakdownLatest FLNA, HELP, ALEC, and NERV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/4/2026ALECAlector Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)5/4/2026ALECAlector Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingUnderweight$2.004/22/2026FLNACassava Sciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/15/2026ALECAlector Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Overweight4/15/2026NERVMinerva Neurosciences Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageMarket Outperform$14.004/13/2026HELPCybin TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy3/27/2026NERVMinerva Neurosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/12/2026NERVMinerva Neurosciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$4.00 ➝ $7.003/10/2026ALECAlector BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$6.003/2/2026HELPCybin HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$55.00 ➝ $95.00(Data available from 5/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALECAlector$21.05M11.18N/AN/A$0.09 per share23.56FLNACassava SciencesN/AN/AN/AN/A$1.41 per shareN/AHELPCybinN/AN/AN/AN/A$7.89 per shareN/ANERVMinerva NeurosciencesN/AN/AN/AN/A($5.45) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALECAlector-$142.93M-$1.19N/AN/AN/A-680.83%-295.17%-40.95%8/6/2026 (Estimated)FLNACassava Sciences-$90.97M-$1.61N/AN/AN/AN/A-53.90%-34.20%N/AHELPCybin-$81.31M-$4.23N/AN/AN/AN/A-59.98%-50.80%N/ANERVMinerva Neurosciences-$293.42M-$29.16N/A1.04N/AN/AN/A-32.63%N/ALatest FLNA, HELP, ALEC, and NERV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026ALECAlector-$0.2878-$0.21+$0.0778-$0.21$9.67 million$1.05 million5/7/2026Q1 2026FLNACassava SciencesN/A-$0.21N/A-$0.21N/AN/A5/5/2026Q1 2026NERVMinerva Neurosciences-$0.13-$0.17-$0.04-$2.86N/AN/A3/12/2026Q4 2025FLNACassava Sciences-$0.30-$0.26+$0.04-$0.26N/AN/A2/25/2026Q4 2025ALECAlector-$0.39-$0.34+$0.05-$0.34$1.78 million$6.24 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALECAlectorN/AN/AN/AN/AN/AFLNACassava SciencesN/AN/AN/AN/AN/AHELPCybinN/AN/AN/AN/AN/ANERVMinerva NeurosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALECAlector0.805.255.25FLNACassava SciencesN/A2.192.19HELPCybinN/A13.7813.78NERVMinerva NeurosciencesN/A17.6517.65Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALECAlector85.83%FLNACassava Sciences38.05%HELPCybin17.94%NERVMinerva Neurosciences34.56%Insider OwnershipCompanyInsider OwnershipALECAlector8.30%FLNACassava Sciences4.60%HELPCybin15.00%NERVMinerva Neurosciences10.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALECAlector270111.03 million101.81 millionOptionableFLNACassava Sciences2048.31 million46.09 millionOptionableHELPCybin5051.63 million43.89 millionN/ANERVMinerva Neurosciences946.59 million41.74 millionNot OptionableFLNA, HELP, ALEC, and NERV HeadlinesRecent News About These CompaniesAll You Need to Know About Minerva Neurosciences (NERV) Rating Upgrade to BuyMay 20 at 1:01 PM | zacks.comMinerva Neurosciences (NERV) Loses 37.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerMay 20 at 10:35 AM | zacks.comMinerva Neurosciences (NASDAQ:NERV) Shares Cross Below 200 Day Moving Average - Here's WhyMay 19 at 4:15 AM | americanbankingnews.comMinerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare ConferenceMay 18 at 4:05 PM | globenewswire.comMinerva Neurosciences (NASDAQ:NERV) Cut to Sell at Wall Street ZenMay 9, 2026 | marketbeat.comMinerva Neurosciences, Inc: Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business UpdatesMay 5, 2026 | finanznachrichten.deMinerva Neurosciences (NASDAQ:NERV) Posts Quarterly Earnings Results, Misses Expectations By $0.04 EPSMay 5, 2026 | marketbeat.comMinerva Neurosciences Provides First Quarter 2026 Financial Results and Business UpdatesMay 5, 2026 | globenewswire.comMinerva Neurosciences, Inc (NASDAQ:NERV) Short Interest UpdateMay 1, 2026 | marketbeat.comMinerva Neurosciences (NERV) price target increased by 31.03% to 9.69April 28, 2026 | msn.comCitizens Initiates Coverage of Minerva Neurosciences (NERV) with Market Outperform RecommendationApril 16, 2026 | msn.comMinerva launched with New Outperform at Citizens on schizophrenia candidateApril 15, 2026 | seekingalpha.comMinerva Neurosciences Sets 2026 Annual Shareholder Meeting TimelineApril 6, 2026 | tipranks.comMinerva Announces Leadership TransitionApril 2, 2026 | globenewswire.comMinerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of SchizophreniaMarch 31, 2026 | globenewswire.comMinerva Neurosciences: Plodding Ahead After Another Roluperidone Delay In Negative Symptoms Of SchizophreniaMarch 31, 2026 | seekingalpha.comMinerva Neurosciences (NERV) price target increased by 61.11% to 7.40March 27, 2026 | msn.comMinerva Neurosciences, Inc: Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026March 25, 2026 | finanznachrichten.deMinerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026March 25, 2026 | globenewswire.comMinerva Neurosciences to Participate in The Stifel 2026 Virtual CNS ForumMarch 12, 2026 | globenewswire.comMinerva Neurosciences, Inc: Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Business UpdatesMarch 11, 2026 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 2026Before the Moon Base Gets Built, These 4 Companies WinBy Thomas Hughes | May 11, 2026Quantum Earnings Season Is Ramping Up—What to Watch From 2 Major PlayersBy Nathan Reiff | May 10, 2026Target the Red-Hot Spin-Off and Merger Space With These ETFsBy Nathan Reiff | May 17, 20262 Ways to Play the Big Pharma Patent CliffBy Nathan Reiff | May 15, 2026FLNA, HELP, ALEC, and NERV Company DescriptionsAlector NASDAQ:ALEC$2.12 +0.01 (+0.47%) Closing price 05/20/2026 04:00 PM EasternExtended Trading$2.12 0.00 (0.00%) As of 05/20/2026 05:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.Cassava Sciences NASDAQ:FLNA$1.25 +0.05 (+4.17%) As of 05/20/2026 04:00 PM EasternFilana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.Cybin NASDAQ:HELP$4.34 +0.16 (+3.83%) Closing price 05/20/2026 04:00 PM EasternExtended Trading$4.30 -0.04 (-1.01%) As of 04:20 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a discovery-phase phenethylamine derivative to treat neuroinflammation and psychiatric conditions. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.Minerva Neurosciences NASDAQ:NERV$5.03 +0.67 (+15.37%) Closing price 05/20/2026 04:00 PM EasternExtended Trading$5.04 +0.01 (+0.22%) As of 05/20/2026 05:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Analog Devices Provides Much-Needed Pullback: How Low Can It Go? USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal Looms From Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 Outlook AI Consolidation Begins: Blackstone & Google Forge an AI Empire The Great AI Rotation: Cashing In on Data Mirum Pharma: A Rare Disease Growth Story to Watch Vertical Aerospace: Pre-Flight Checks Point to a Breakout HIVE Weaponizes Power for an AI Pivot Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
